Focus on cardiac amyloidosis
- 1 April 2013
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cardiovascular Medicine
- Vol. 14 (4), 281-288
- https://doi.org/10.2459/jcm.0b013e3283536534
Abstract
AIM: Amyloidosis is a systemic disease, related to different underlying causes, with frequent cardiac involvement. Clinical evaluation, echocardiography and electrocardiography represent important noninvasive tools in identification of cardiac involvement. The aim of this study was to assess the clinical-laboratory features of a series of patients affected by cardiac amyloidosis in order to evaluate the risk of cardiac mortality. METHODS: We evaluated 48 patients (men 65%, mean age 63 ± 11 years) with biopsy-proven diagnosis of amyloidosis and heart involvement observed from 1991 to 2009. All patients underwent clinical-laboratory evaluation at baseline and were followed up. RESULTS: During a median follow-up of 9.5 months (first to third interquartile: 3-41.5 months), 24 patients (50%) died as a result of a cardiac cause. Survival free from cardiac death was 69, 50, 48 and 41% at 6, 12, 24 and 60 months from diagnosis, respectively. At multivariable Cox regression analysis, the presence of heart failure at enrolment [hazard ratio (HR) 4.67, 95% confidence interval (CI) 1.07-20.27, P = 0.04] and history of recent syncope (HR 3.97, 95% CI 1.28-12.34, P = 0.017) emerged as independent predictors of cardiac death. By using the equation derived from the multivariate analysis, individual survival probability at different times of follow-up was calculated. CONCLUSION: We confirm the particularly poor outcome of cardiac amyloidosis in the short term. A careful clinical evaluation emerges as the most important tool for the prognostic stratification and quantification of risk in patients with cardiac amyloidosisKeywords
This publication has 29 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡European Journal of Heart Failure, 2008
- Evaluation and Management of the Cardiac AmyloidosisJournal of the American College of Cardiology, 2007
- Diagnosis and Management of the Cardiac AmyloidosesCirculation, 2005
- Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosisAmyloid, 2005
- Longitudinal Myocardial Function Assessed by Tissue Velocity, Strain, and Strain Rate Tissue Doppler Echocardiography in Patients With AL (Primary) Cardiac AmyloidosisCirculation, 2003
- Eligibility for Hematopoietic Stem-Cell Transplantation for Primary Systemic Amyloidosis Is a Favorable Prognostic Factor for SurvivalJournal of Clinical Oncology, 2001
- Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosisThe American Journal of Cardiology, 1996
- Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement and relation to survivalJournal of the American College of Cardiology, 1985
- Cardiac amyloidosis causing cardiac dysfunction: Analysis of 54 necropsy patientsThe American Journal of Cardiology, 1983
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation, 1978